

**Table 1: Demographics of Infants Eligible for RSV Immunity**

Demographic/Clinical Characteristic	2023-24	2024-25	P-value
Total Eligible Infants* (n)	1,653	1,692	
Immune (n,%)			<b>&lt;0.001</b>
Yes	789 (47.7%)	1,023 (60.5%)	
No	864 (52.3%)	669 (39.5%)	
Type of Immunity (n,%)			<b>&lt;0.001</b>
Nirsevimab	762 (46.1%)	917 (54.2%)	
Passive (Mother vaccinated during pregnancy)**	27 (1.6%)	106 (6.3%)	
None	864 (52.3%)	669 (39.5%)	
Location Nirsevimab Administered (n,%)			<b>0.035</b>
Primary Care	762 (100.0%)	911 (99.3%)	
External	0 (0.0%)	6 (0.7%)	
Age at Immunization (median, IQR; days)	54 (11, 132)	46 (7, 128)	<b>0.022</b>
Gender (n,%)			0.784
Male	848 (51.3%)	860 (50.8%)	
Female	805 (48.7%)	832 (49.2%)	
Race (n,%)			<b>&lt;0.001</b>
Black	1,090 (65.9%)	1,084 (64.1%)	
Other/Unknown***	296 (17.9%)	389 (23.0%)	
White	267 (16.2%)	219 (12.9%)	
Ethnicity (n,%)			<b>&lt;0.001</b>
Hispanic	150 (9.07%)	228 (13.5%)	
Non-Hispanic	1,400 (84.7%)	1,438 (85.0%)	
Unknown	191 (6.11%)	26 (1.5%)	
Insurance Type (n,%)			<b>0.033</b>
Public	1,378 (83.4%)	1,387 (82.0%)	
Private	89 (5.4%)	128 (7.6%)	
Self-Pay	186 (11.3%)	177 (10.5%)	
Social Risk Screen (n,%)			0.280
Positive	838 (50.7%)	878 (51.9%)	
Negative	647 (39.1%)	626 (37.0%)	
Missing	168 (10.2%)	148 (8.7%)	

Footnote:

\*Eligibility determined by: infants <8 months of age and had primary care visit during nirsevimab administration season (October 12 – March 31 in 2023-24 season and October 1-March 31 in the 2024-25 season)

\*\*Maternal vaccination determined by EHR documentation in infant’s chart why BPA alert for nirsevimab administration was suppressed

\*\*\*Other race includes: multiracial, Asian, Middle Eastern, Native Hawaiian/Pacific Islander, American Indian/Alaska Native, Unknown